dipyridamole has been researched along with Ischemic Attack, Transient in 194 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 9.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "We showed that slower than standard dose escalation of dipyridamole in combination therapy with acetylsalicylic acid does not reduce headaches as a side effect." | 9.19 | The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). ( de Vogel, EM; de Vos-Koppelaar, NC; Dieleman, HG; Kerkhoff, H; Zock, E, 2014) |
| " Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole." | 9.15 | Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2011) |
| "Secondary pharmacological prevention of ischemic stroke or transient ischemic attack (TIA) is often provided with acetylsalicylic acid (ASA), dipyridamole (DP) or a combination of the two." | 9.14 | Dipyridamole-associated headache in stroke patients--interindividual differences? ( Lökk, J, 2009) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Combination of low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over aspirin alone." | 9.12 | Dose titration to reduce dipyridamole-related headache. ( Chang, YJ; Lee, TH; Ryu, SJ, 2006) |
| "We performed meta-analyses to assess the effectiveness and safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke of presumed arterial origin within one week and six months." | 8.89 | The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. ( Li, X; Zhou, G; Zhou, S; Zhou, X, 2013) |
| "The combination of aspirin and dipyridamole is more effective than aspirin alone in patients with TIA or ischaemic stroke of presumed arterial origin in the secondary prevention of stroke and other vascular events." | 8.84 | Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. ( Algra, A; Bath, PM; Diener, HC; Gray, LJ; Guiraud-Chaumeil, B; Halkes, PH; Yatsu, FM, 2008) |
| "This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events." | 8.84 | Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. ( Gorelick, PB; Nguyen, D; Verro, P, 2008) |
| "Dipyridamole, given alone or with aspirin, reduces stroke recurrence in patients with previous ischemic cerebrovascular disease." | 8.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 8.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Long term triple antiplatelet therapy was asociated with a significant increase in adverse events and bleeding rates, and their severity, and a trend to increased discontinuations." | 6.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 5.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "This is the first case report of a circulatory collapse induced by an oral intake of dipyridamole." | 5.48 | Oral Dipyridamole-Associated Circulatory Collapse. ( Jolma, P; Ollikainen, J; Uurto, I, 2018) |
| "The European/Australasian stroke prevention in reversible ischaemia trial (ESPRIT) confirms that long-term administration of the combination acetylsalicylic acid and dipyridamole is more effective than acetylsalicylic acid in reducing the risk of vascular events after cerebral ischaemia of arterial origin." | 5.33 | [The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed]. ( De Keyser, JH; Luijckx, GJ, 2006) |
| "We showed that slower than standard dose escalation of dipyridamole in combination therapy with acetylsalicylic acid does not reduce headaches as a side effect." | 5.19 | The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). ( de Vogel, EM; de Vos-Koppelaar, NC; Dieleman, HG; Kerkhoff, H; Zock, E, 2014) |
| " Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole." | 5.15 | Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2011) |
| "Secondary pharmacological prevention of ischemic stroke or transient ischemic attack (TIA) is often provided with acetylsalicylic acid (ASA), dipyridamole (DP) or a combination of the two." | 5.14 | Dipyridamole-associated headache in stroke patients--interindividual differences? ( Lökk, J, 2009) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Combination of low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over aspirin alone." | 5.12 | Dose titration to reduce dipyridamole-related headache. ( Chang, YJ; Lee, TH; Ryu, SJ, 2006) |
| "Results of trials of aspirin and dipyridamole combined versus aspirin alone for the secondary prevention of vascular events after ischaemic stroke of presumed arterial origin are inconsistent." | 5.12 | Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2006) |
| "The second European Stroke Prevention Study investigated the prevention of stroke and/or death in 6602 patients with transient ischaemic attack or stroke with aspirin (25 mg b." | 5.09 | Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). ( Bertrand-Hardy, JM; Darius, H; Diener, HC; Humphreys, M, 2001) |
| "Combination therapy with dipyridamole and aspirin reduces not only the risk of cerebrovascular ischemic events but also the risk of myocardial infarction." | 5.07 | Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event. ( Laakso, M; Lowenthal, A; Riekkinen, PJ; Sivenius, J; Smets, P, 1993) |
| "We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years." | 5.06 | European Stroke Prevention Study. ESPS Group. ( , 1990) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| "We performed meta-analyses to assess the effectiveness and safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke of presumed arterial origin within one week and six months." | 4.89 | The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. ( Li, X; Zhou, G; Zhou, S; Zhou, X, 2013) |
| "The combination of aspirin and dipyridamole is more effective than aspirin alone in patients with TIA or ischaemic stroke of presumed arterial origin in the secondary prevention of stroke and other vascular events." | 4.84 | Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. ( Algra, A; Bath, PM; Diener, HC; Gray, LJ; Guiraud-Chaumeil, B; Halkes, PH; Yatsu, FM, 2008) |
| "Low dose aspirin is effective in secondary stroke prevention." | 4.84 | Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. ( Kirshner, HS, 2007) |
| "This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events." | 4.84 | Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. ( Gorelick, PB; Nguyen, D; Verro, P, 2008) |
| "Dipyridamole, given alone or with aspirin, reduces stroke recurrence in patients with previous ischemic cerebrovascular disease." | 4.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| " The search terms used were dipyridamole, aspirin, acetylsalicylic acid, ischemic stroke, and cerebrovascular disorders." | 4.81 | Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke. ( Redman, AR; Ryan, GJ, 2001) |
| " Dipyridamole co-formulated with aspirin has been shown to increase the relative reduction in risk of second stroke in patients with prior stroke/transient ischaemic attack beyond that obtaining with aspirin alone." | 4.81 | Dipyridamole may be used safely in patients with ischaemic heart disease. ( Bertrand-Hardy, JM; Humphreys, DM; Palluk, R; Schumacher, H; Street, J, 2002) |
| "Aspirin is the treatment of first choice for long-term secondary prevention of vascular events in patients with confirmed non-cardioembolic ischaemic stroke or TIA." | 4.80 | Prevention of ischaemic stroke--antiplatelets. ( Brown, MM; McCabe, DJ, 2000) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 4.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| "Clopidogrel and dipyridamole-aspirin are used frequently after stroke or transient ischemic attack." | 3.74 | Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack. ( Hills, NK; Johnston, SC, 2008) |
| "Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole." | 3.71 | Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001) |
| "Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack." | 3.70 | Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| "In these patients with type 2 diabetes and a history of TIA, patterns of platelet inhibition differed significantly according to whether treatment was with ER-DP+ASA or clopidogrel with or without ASA." | 2.73 | Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b ( Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL, 2008) |
| "Long term triple antiplatelet therapy was asociated with a significant increase in adverse events and bleeding rates, and their severity, and a trend to increased discontinuations." | 2.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "Dipyridamole was associated with a slight increase in headache, which resolved in most patients if therapy was continued." | 2.69 | Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. ( Forbes, CD, 1998) |
| "Patients with prior stroke or transient ischemic attack (TIA) were randomized to treatment with ASA alone (50 mg daily), modified-release dipyridamole alone (400 mg daily), the two agents in a combined formulation, or placebo." | 2.68 | European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. ( Cunha, L; Diener, HC; Forbes, C; Lowenthal, A; Sivenius, J; Smets, P, 1996) |
| "Bleeding is the main adverse effect of antiplatelet therapy and is potentially life threatening." | 2.53 | Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| "Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone." | 2.46 | Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. ( Fung, K; Simmons, BB; Yeo, A, 2010) |
| "Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States." | 2.44 | Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008) |
| "Patients who have transient ischemic attack (TIA) or ischemic stroke are at a high risk of having a first or recurrent stroke." | 2.44 | Antiplatelet agents and randomized trials. ( Diener, HC, 2007) |
| "Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke." | 2.41 | Update on antiplatelet therapy for stroke prevention. ( Elkind, MS; Sacco, RL, 2000) |
| "Dipyridamole can inhibit both platelet adhesion and aggregation by raising the platelet cyclic AMP level through phosphodiesterase inhibition." | 2.37 | Aspirin and other platelet-aggregation inhibiting drugs. ( Gallus, AS, 1985) |
| "This is the first case report of a circulatory collapse induced by an oral intake of dipyridamole." | 1.48 | Oral Dipyridamole-Associated Circulatory Collapse. ( Jolma, P; Ollikainen, J; Uurto, I, 2018) |
| "Dipyridamole is an antiplatelet agent and a vasodilator which is increasingly being used for the secondary prevention of ischaemic stroke and transient ischemic attack, either alone or in combination with acetylsalicylic acid." | 1.34 | Musical hallucinations induced by drugs. ( Cheung, G; Tomar, A, 2007) |
| "Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year." | 1.33 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006) |
| "The European/Australasian stroke prevention in reversible ischaemia trial (ESPRIT) confirms that long-term administration of the combination acetylsalicylic acid and dipyridamole is more effective than acetylsalicylic acid in reducing the risk of vascular events after cerebral ischaemia of arterial origin." | 1.33 | [The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed]. ( De Keyser, JH; Luijckx, GJ, 2006) |
| "62 patients with transient ischemic attack (TIA), 60 with reversible ischemic neurologic deficit (RIND) and 57 with stroke with minimum residuum (SMR) were followed, in a retrospective survey, from the first 7 days to the 3rd month of evolution." | 1.27 | Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum. ( Calandre, L; Molina, JA, 1985) |
| "Recurrent transient ischemic attack or amaurosis fugax occurred more frequently (P less than 0." | 1.27 | Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. ( Eriksson, SE, 1985) |
| "In patients with transient ischemic attack (TIA), the risk of stroke increases greatly, especially in the months immediately following the initial attack." | 1.27 | Transient ischemic attacks. Strategies for minimizing stroke risk. ( Furlan, AJ, 1984) |
| "and sulfinpyrazone have been tested in several large scale clinical trials." | 1.26 | [Antiplatelet drugs (author's transl)]. ( Dechavanne, M; Follea, G; Trzeciak, MC, 1979) |
| "Eight patients with transient ischemic attacks, and three with partial nonprogressive strokes associated with mitral valve prolapse, are reported." | 1.26 | TIA, stroke, and mitral valve prolapse. ( Watson, RT, 1979) |
| "In patients with transient ischemic attacks, particularly males with appropriate carotid lesions, aspirin therapy reduces the frequency of transient ischemic attacks and possibly the incidence of stroke and death." | 1.26 | [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. ( Oelz, O, 1979) |
| "The authors report 22 cases of transient ischemic attacks (TIA's) manifested by amaurosis fugax or hemiparesis or paresthesia of less than 24 hours' duration." | 1.26 | Transient ischemic attacks due to increased platelet aggregation and adhesiveness. Ultrastructural and functional correlation. ( al-Mefty, O; Marano, G; Nugent, GR; Raiaraman, S; Rodman, N, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 73 (37.63) | 18.7374 |
| 1990's | 21 (10.82) | 18.2507 |
| 2000's | 69 (35.57) | 29.6817 |
| 2010's | 25 (12.89) | 24.3611 |
| 2020's | 6 (3.09) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, MK | 1 |
| Cha, JK | 1 |
| Chang, DI | 1 |
| Kim, HY | 1 |
| Chung, JW | 1 |
| Jung, KH | 1 |
| Hong, KS | 2 |
| Chang, JY | 1 |
| Rha, JH | 1 |
| Park, JM | 1 |
| Kim, BK | 1 |
| Lee, SJ | 1 |
| Park, MS | 1 |
| Lee, KY | 1 |
| Shin, DI | 1 |
| Yoon, BW | 1 |
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Lim, ST | 1 |
| Murphy, SJX | 1 |
| Murphy, SM | 1 |
| Coughlan, T | 5 |
| O'Neill, D | 5 |
| Tierney, S | 4 |
| Egan, B | 4 |
| Collins, DR | 4 |
| McCarthy, AJ | 1 |
| Lim, SY | 1 |
| Smith, DR | 1 |
| Cox, D | 2 |
| McCabe, DJH | 1 |
| Scalia, L | 1 |
| Calderone, D | 1 |
| Capodanno, D | 1 |
| Woodhouse, LJ | 2 |
| Appleton, JP | 2 |
| Christensen, H | 2 |
| Dineen, RA | 2 |
| England, TJ | 2 |
| James, M | 2 |
| Krishnan, K | 2 |
| Montgomery, AA | 2 |
| Ranta, A | 2 |
| Robinson, TG | 2 |
| Sprigg, N | 3 |
| Bath, PM | 6 |
| Hilkens, NA | 2 |
| Algra, A | 9 |
| Diener, HC | 17 |
| Csiba, L | 1 |
| Hacke, W | 1 |
| Kappelle, LJ | 2 |
| Koudstaal, PJ | 2 |
| Leys, D | 2 |
| Mas, JL | 1 |
| Sacco, RL | 3 |
| Greving, JP | 2 |
| Beridze, M | 1 |
| Duley, L | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 1 |
| Markus, HS | 1 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Scutt, P | 1 |
| Venables, GS | 1 |
| Jolma, P | 1 |
| Ollikainen, J | 1 |
| Uurto, I | 1 |
| Zuurbier, SM | 1 |
| Vermeer, SE | 1 |
| Hilkens, PH | 1 |
| Roos, YB | 1 |
| Edwards, D | 1 |
| Fletcher, K | 1 |
| Deller, R | 1 |
| McManus, R | 1 |
| Lasserson, D | 1 |
| Giles, M | 1 |
| Sims, D | 1 |
| Norrie, J | 1 |
| McGuire, G | 1 |
| Cohn, S | 1 |
| Whittle, F | 1 |
| Hobbs, V | 1 |
| Weir, C | 1 |
| Mant, J | 1 |
| Li, X | 1 |
| Zhou, G | 1 |
| Zhou, X | 1 |
| Zhou, S | 1 |
| Lee, M | 1 |
| Saver, JL | 1 |
| Rao, NM | 1 |
| Wu, YL | 1 |
| Ovbiagele, B | 1 |
| Ding, D | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Tobin, WO | 4 |
| Kinsella, JA | 4 |
| Kavanagh, GF | 2 |
| O'Donnell, JS | 2 |
| McGrath, RT | 1 |
| Feeley, TM | 3 |
| Murphy, RP | 4 |
| McCabe, DJ | 5 |
| de Vos-Koppelaar, NC | 1 |
| Kerkhoff, H | 1 |
| de Vogel, EM | 1 |
| Zock, E | 1 |
| Dieleman, HG | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Halkes, PH | 2 |
| Gray, LJ | 2 |
| Guiraud-Chaumeil, B | 3 |
| Yatsu, FM | 2 |
| England, T | 1 |
| Willmot, MR | 1 |
| Zhao, L | 1 |
| Sare, GM | 1 |
| Lam, SK | 1 |
| Owen, A | 1 |
| Vande Griend, JP | 1 |
| Saseen, JJ | 1 |
| Rouhl, RP | 1 |
| Lodder, J | 1 |
| Biller, J | 1 |
| Khalil, S | 1 |
| Mohanaruban, K | 1 |
| Haq, S | 1 |
| Lökk, J | 1 |
| Schwab, S | 1 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Dengler, R | 1 |
| Schwartz, A | 1 |
| Grond, M | 1 |
| Schumacher, H | 2 |
| Machnig, T | 1 |
| Eschenfelder, CC | 1 |
| Leonard, J | 1 |
| Weissenborn, K | 1 |
| Kastrup, A | 1 |
| Haberl, R | 1 |
| Simmons, BB | 1 |
| Yeo, A | 1 |
| Fung, K | 1 |
| Kral, M | 1 |
| Herzig, R | 1 |
| Sanak, D | 1 |
| Skoloudik, D | 1 |
| Vlachova, I | 1 |
| Bartkova, A | 1 |
| Hlustik, P | 1 |
| Kovacik, M | 1 |
| Kanovsky, P | 1 |
| Charles, J | 1 |
| Pan, Y | 1 |
| Miller, G | 1 |
| Weber, R | 1 |
| Weimar, C | 1 |
| Röther, J | 1 |
| Guthrie, R | 1 |
| Chaturvedi, S | 1 |
| Bhattacharya, P | 1 |
| Aw, D | 1 |
| Sharma, JC | 1 |
| Acelajado, MC | 1 |
| Oparil, S | 1 |
| Collins, R | 1 |
| Molnar, T | 2 |
| Szabo, Z | 1 |
| Bartha, E | 1 |
| Illes, Z | 1 |
| McGrath, RA | 1 |
| De Schryver, EL | 4 |
| van Gijn, J | 5 |
| Moonis, M | 1 |
| Fisher, M | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Leonardi-Bee, J | 1 |
| Bousser, MG | 3 |
| Davalos, A | 1 |
| Sivenius, J | 11 |
| Yatsu, F | 1 |
| Dewey, ME | 1 |
| Wiersma, TJ | 1 |
| van Binsbergen, JJ | 1 |
| Verhoeven, S | 1 |
| van Bentum, ST | 1 |
| Goudswaard, AN | 1 |
| Houben, J | 1 |
| Bernstein, RA | 1 |
| Gebel, JM | 1 |
| Sudlow, C | 2 |
| Fieschi, C | 2 |
| Volante, F | 1 |
| Chang, YJ | 1 |
| Ryu, SJ | 1 |
| Lee, TH | 1 |
| Luijckx, GJ | 1 |
| De Keyser, JH | 2 |
| Cordonnier, C | 1 |
| Schrama, E | 1 |
| Eusman, JP | 1 |
| Offerhaus, L | 1 |
| Liao, JK | 1 |
| de Borst, GJ | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| Moll, FL | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Macdonald, S | 1 |
| Tomar, A | 1 |
| Cheung, G | 1 |
| Fintel, DJ | 1 |
| Kirshner, HS | 1 |
| Overgaard, K | 1 |
| Poulsen, TS | 1 |
| Husted, SE | 1 |
| Weinberger, J | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Adams, RJ | 1 |
| Albers, G | 1 |
| Alberts, MJ | 1 |
| Benavente, O | 1 |
| Furie, K | 1 |
| Goldstein, LB | 1 |
| Gorelick, P | 1 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Johnston, SC | 2 |
| Katzan, I | 1 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Schwamm, LH | 1 |
| Hills, NK | 1 |
| Verro, P | 1 |
| Gorelick, PB | 1 |
| Nguyen, D | 1 |
| Serebruany, VL | 1 |
| Malinin, AI | 1 |
| Pokov, AN | 1 |
| Hanley, DF | 1 |
| Thijs, V | 1 |
| Lemmens, R | 1 |
| Fieuws, S | 1 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Skliut, M | 1 |
| Jamieson, DG | 1 |
| Genton, E | 2 |
| Herskovits, E | 4 |
| Vazquez, A | 3 |
| Famulari, A | 4 |
| Smud, R | 2 |
| Tamaroff, L | 4 |
| Fraiman, H | 4 |
| Gonzalez, AM | 3 |
| Vila, J | 4 |
| Matera, V | 3 |
| Hinton, RC | 1 |
| Stewart, ME | 1 |
| Douglas, JT | 1 |
| Lowe, GD | 1 |
| Prentice, CR | 1 |
| Forbes, CD | 3 |
| Aushri, Z | 1 |
| Berginer, V | 1 |
| Nathan, I | 1 |
| Dvilansky, A | 1 |
| Wilkerson, RJ | 1 |
| Liem, PH | 1 |
| Carter, WJ | 1 |
| Linder, M | 1 |
| Lechner, H | 1 |
| Ott, E | 1 |
| Bertha, G | 1 |
| Ramirez-Lassepas, M | 1 |
| Kistler, JP | 1 |
| Ropper, AH | 1 |
| Heros, RC | 1 |
| Eichner, ER | 1 |
| Rushton, FW | 1 |
| Kukora, JS | 1 |
| Solvay, H | 1 |
| Kahn, M | 1 |
| Selosse, P | 1 |
| Carlier, J | 1 |
| Cloarec, M | 1 |
| Delwiche, JP | 1 |
| Fenollar, J | 1 |
| Donaldson, IM | 1 |
| Furlan, AJ | 2 |
| Gonzáles, AM | 1 |
| Rascol, A | 2 |
| David, J | 2 |
| Boneu, B | 2 |
| Clanet, M | 1 |
| Bierme, R | 2 |
| Yeung Laiwah, AC | 1 |
| Passamani, ER | 1 |
| Brechter, C | 1 |
| Bäcklund, H | 1 |
| Krook, H | 1 |
| Müller, R | 1 |
| Nitelius, E | 1 |
| Olsson, JE | 2 |
| Olsson, O | 1 |
| Thornberg, A | 1 |
| Eschwege, E | 1 |
| Haguenau, M | 1 |
| Lefauconnier, JM | 1 |
| Touboul, D | 1 |
| Touboul, PJ | 1 |
| Hansen, PE | 1 |
| Hansen, JH | 1 |
| Stenbjerg, S | 1 |
| Marshall, M | 1 |
| Tomlin, P | 1 |
| Newton, R | 1 |
| Sørensen, PS | 1 |
| Marquardsen, J | 1 |
| De Marinis, M | 1 |
| Prencipe, M | 2 |
| Falchetti, R | 1 |
| Paolucci, S | 1 |
| Riekkinen, PJ | 7 |
| Laakso, M | 9 |
| Lette, J | 1 |
| Carini, G | 1 |
| Tatum, JL | 1 |
| Paquet, N | 1 |
| Bisson, G | 1 |
| Picard, M | 1 |
| Bom, HS | 1 |
| Lusa, AM | 1 |
| Labanti, G | 1 |
| Teitelbaum, J | 1 |
| Lowenthal, A | 6 |
| Smets, P | 6 |
| Cunha, L | 2 |
| Forbes, C | 2 |
| Gibbs, CR | 1 |
| Li-Saw-Hee, FL | 1 |
| Lip, GY | 1 |
| Puranen, J | 2 |
| Riekkinen, P | 2 |
| Gorter, JW | 1 |
| Mosso, M | 1 |
| Baumgartner, RW | 2 |
| Hughes, RL | 1 |
| Elkind, MS | 1 |
| Sarasin, FP | 1 |
| Gaspoz, JM | 1 |
| Bounameaux, H | 1 |
| Bergmann, SR | 1 |
| Brown, MM | 1 |
| Siegel, AM | 1 |
| Sandor, P | 1 |
| Kollias, SS | 1 |
| Zámbó, K | 1 |
| Schmidt, E | 1 |
| Tekeres, M | 1 |
| Scheen, AJ | 1 |
| Darius, H | 2 |
| Bertrand-Hardy, JM | 3 |
| Humphreys, M | 2 |
| Redman, AR | 1 |
| Ryan, GJ | 1 |
| Lalouschek, W | 1 |
| Lang, W | 1 |
| Müllner, M | 1 |
| Humphreys, DM | 1 |
| Street, J | 1 |
| Palluk, R | 1 |
| Fabris, F | 2 |
| Pernigotti, L | 1 |
| Dougherty, JH | 1 |
| Levy, DE | 1 |
| Weksler, BB | 1 |
| Deykin, D | 1 |
| Gurewich, V | 1 |
| Harker, L | 1 |
| Hirsch, J | 1 |
| Sandok, BA | 1 |
| Whisnant, JP | 1 |
| Sundt, TM | 1 |
| Hirsh, J | 2 |
| Fassio, G | 1 |
| Albizzati, MG | 1 |
| Bassi, S | 1 |
| Frattola, L | 1 |
| Mitchell, JR | 1 |
| Ostendorf, P | 1 |
| al-Mefty, O | 1 |
| Marano, G | 1 |
| Raiaraman, S | 1 |
| Nugent, GR | 1 |
| Rodman, N | 1 |
| Oelz, O | 1 |
| Dechavanne, M | 1 |
| Follea, G | 1 |
| Trzeciak, MC | 1 |
| Burén, A | 1 |
| Ygge, J | 1 |
| Watson, RT | 1 |
| Mazal, S | 1 |
| Simons, L | 1 |
| Mustard, JF | 1 |
| Packham, MA | 1 |
| Kinlough-Rathbone, RL | 1 |
| Wu, KK | 1 |
| Hoak, JC | 1 |
| Gent, M | 1 |
| Harker, LA | 2 |
| Kendall, MJ | 1 |
| De La Cruz, JP | 1 |
| Villalobos, MA | 1 |
| Carrasco, T | 1 |
| Smith-Agreda, JM | 1 |
| Sánchez de la Cuesta, F | 1 |
| Kilpeläinen, H | 1 |
| Penttilä, I | 1 |
| Stachenko, SJ | 1 |
| Bravo, G | 1 |
| Côté, R | 1 |
| Boucher, J | 1 |
| Battista, RN | 1 |
| Penttilä, IM | 1 |
| Loherstorfer, E | 1 |
| Seboldt, H | 1 |
| Dichgans, J | 1 |
| Inzitari, D | 1 |
| Fratiglioni, L | 1 |
| Baldereschi, M | 1 |
| Candelise, L | 1 |
| Anzalone, N | 1 |
| Bonatti, ML | 1 |
| Gandolfo, C | 1 |
| Mamoli, A | 1 |
| Rasura, M | 1 |
| Randi, ML | 1 |
| Casonato, A | 1 |
| Dal Bo Zanon, R | 1 |
| Manzoni, S | 1 |
| Tonin, P | 1 |
| De Zanche, L | 1 |
| Girolami, A | 1 |
| Edwards, WH | 2 |
| Mulherin, JL | 1 |
| Jenkins, JM | 1 |
| Calandre, L | 1 |
| Molina, JA | 1 |
| Vzquez, A | 1 |
| Dominguez, R | 2 |
| Benjamin, V | 1 |
| Levine, SR | 1 |
| Langer, SL | 1 |
| Albers, JW | 1 |
| Welch, KM | 1 |
| Sze, PC | 1 |
| Reitman, D | 1 |
| Pincus, MM | 1 |
| Sacks, HS | 1 |
| Chalmers, TC | 1 |
| Mazzei, B | 1 |
| Carelli, A | 1 |
| Gaudio, G | 1 |
| Stellato, G | 1 |
| Cundari, E | 1 |
| Corsonello, F | 1 |
| De Martiis, M | 1 |
| Parenzi, A | 1 |
| Barlattani, A | 1 |
| De Martiis, A | 1 |
| Freeman, JW | 1 |
| Rosenthal, D | 1 |
| Lamis, PA | 1 |
| Stanton, PE | 1 |
| Clark, MD | 1 |
| Ellison, RG | 1 |
| Kasuya, A | 1 |
| Holm, K | 1 |
| Geeraert, AJ | 1 |
| Al Saigh, AH | 1 |
| Gallus, AS | 1 |
| Sherry, S | 1 |
| Shaw, MD | 1 |
| Foy, PM | 1 |
| Conway, M | 1 |
| Pickard, JD | 1 |
| Maloney, P | 1 |
| Spillane, JA | 1 |
| Chadwick, DW | 1 |
| Eriksson, SE | 1 |
| Cantu, RC | 1 |
| Snyder, M | 1 |
| Géraud, J | 1 |
| Guiraud, B | 1 |
| Fernet, P | 1 |
| Géraud, G | 1 |
| Lereboullet, J | 1 |
| Rosa, A | 1 |
| Olivier-Martin, R | 1 |
| Millikan, CH | 1 |
| Acheson, J | 1 |
| Danta, G | 1 |
| Hutchinson, EC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox [NCT00562588] | Phase 4 | 551 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial[NCT00161070] | Phase 4 | 4,500 participants | Interventional | 1997-07-31 | Completed | ||
| Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI[NCT00767663] | Phase 4 | 30 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Technical Development for Pediatric Cardiovascular MRI[NCT02892136] | 5,000 participants (Anticipated) | Observational | 2013-05-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke. (NCT00562588)
Timeframe: Baseline and day 8
| Intervention | mL (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | -0.0600 |
| Aggrenox | 0.0000 |
MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke. (NCT00562588)
Timeframe: Baseline and day 90
| Intervention | mL (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | -0.8400 |
| Aggrenox | -0.7100 |
MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR). (NCT00562588)
Timeframe: Baseline and day 8
| Intervention | mL (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 0.4100 |
| Aggrenox | 0.3300 |
MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR). (NCT00562588)
Timeframe: Baseline and day 90
| Intervention | mL (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 0.1900 |
| Aggrenox | 0.1150 |
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead) (NCT00562588)
Timeframe: Baseline and 90 days
| Intervention | Units on a scale (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | -2 |
| Aggrenox | -2 |
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead) (NCT00562588)
Timeframe: Baseline and 8 days
| Intervention | units on a scale (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | -1.0 |
| Aggrenox | -1.0 |
Changes of special biochemical laboratory value (MCP-1) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory (NCT00562588)
Timeframe: 8 days
| Intervention | µg/mL (Geometric Mean) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 1.06 |
| Aggrenox | 1.08 |
Changes of special biochemical laboratory values (CRP) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory (NCT00562588)
Timeframe: 8 days
| Intervention | mg/L (Geometric Mean) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 1.27 |
| Aggrenox | 1.17 |
Changes of special biochemical laboratory value (MMP-9) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory (NCT00562588)
Timeframe: 8 days
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 0.974 |
| Aggrenox | 0.983 |
(NCT00562588)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 38 |
| Aggrenox | 28 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead) (NCT00562588)
Timeframe: 90 days
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | |
| Aggrenox | 70 | 84 | 62 | 16 | 32 | 4 | 5 |
| Aspirin for 7 Days, Followed by Aggrenox | 58 | 75 | 50 | 30 | 31 | 6 | 4 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead) (NCT00562588)
Timeframe: 8 days
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | Missing | |
| Aggrenox | 47 | 74 | 52 | 38 | 44 | 8 | 2 | 8 |
| Aspirin for 7 Days, Followed by Aggrenox | 46 | 59 | 42 | 39 | 51 | 12 | 0 | 5 |
53 reviews available for dipyridamole and Ischemic Attack, Transient
| Article | Year |
|---|---|
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolyt | 2022 |
[Secondary prevention with clopidogrel after TIA or stroke].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; N | 2013 |
The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.
Topics: Aged; Aspirin; Dipyridamole; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; | 2013 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole; | 2016 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; I | 2008 |
Combination antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat | 2008 |
ESPRIT: is aspirin plus dipyridamole superior to aspirin alone in TIA or minor stroke patients?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; H | 2008 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Topics: American Heart Association; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; I | 2010 |
Oral antiplatelet therapy in stroke prevention. Minireview.
Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Drug Combinations; Humans; Ischemic Attack | 2010 |
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Chronic Disease; Clopidogrel; Delayed-Act | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
New insights in antiplatelet therapy for patients with ischemic stroke.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I | 2011 |
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati | 2012 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2003 |
Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Human | 2003 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is | 2005 |
What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack?
Topics: Aspirin; Dipyridamole; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Platelet Aggrega | 2005 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2006 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient | 2007 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2007 |
Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' resu
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, C | 2007 |
Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Family P | 2007 |
Antiplatelet agents and randomized trials.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; P | 2007 |
Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggre | 2008 |
Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggre | 2008 |
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi | 2008 |
Current therapy of cerebrovascular disease.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Ische | 1984 |
Therapeutical aspects of cerebrovascular disease.
Topics: Aspirin; Blood Coagulation; Cerebrovascular Disorders; Clofibrate; Dipyridamole; Erythrocyte Aggrega | 1983 |
Platelet inhibitors for TIAs. A review of prospective drug trial results.
Topics: Aged; Aspirin; Clofibrate; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemic Attack, | 1984 |
Therapy of ischemic cerebral vascular disease due to atherothrombosis. (2).
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Auscultation; Basilar Artery; Blood Platelets; | 1984 |
Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets.
Topics: Angina Pectoris; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Carotid Artery Thrombosi | 1984 |
Antiplatelet drugs in secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Huma | 1998 |
[Transient ischemic attacks and prolonged reversible ischemic neurologic deficit. Diagnosis, differential diagnosis and treatment].
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Dipyridamole; Endarterectomy, | 2000 |
Update on antiplatelet therapy for stroke prevention.
Topics: Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Dose-Response Relation | 2000 |
Prevention of ischaemic stroke--antiplatelets.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Pl | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
[Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemic A | 2000 |
Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; Humans; I | 2001 |
Dipyridamole may be used safely in patients with ischaemic heart disease.
Topics: Dipyridamole; Humans; Ischemic Attack, Transient; Myocardial Ischemia; Randomized Controlled Trials | 2002 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts).
Topics: Animals; Antidepressive Agents, Tricyclic; Aspirin; Blindness; Blood Platelets; Cerebrovascular Diso | 1975 |
Aspirin in transient ischemic attacks and minor stroke: a meta-analysis.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 1991 |
[Study Group: "Evaluation of the efficacy of therapeutic treatments in cerebrovascular diseases"].
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Female; | 1990 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
The management of TIAs in 1986.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Dipyridamo | 1986 |
Aspirin and other platelet-aggregation inhibiting drugs.
Topics: Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Female; Heart Valv | 1985 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
52 trials available for dipyridamole and Ischemic Attack, Transient
| Article | Year |
|---|---|
Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial.
Topics: Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Headache; Humans; Ischemic At | 2022 |
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
RApid Primary care Initiation of Drug treatment for Transient Ischaemic Attack (RAPID-TIA): study protocol for a pilot randomised controlled trial.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Clinical Protocols; Dipyridamole; Drug Admi | 2013 |
The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE).
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Headache; Humans; Ischemic Attack, Transie | 2014 |
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Drug Tolerance; | 2008 |
Dipyridamole-associated headache in stroke patients--interindividual differences?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Dipyridamole; Drug Therapy, Combination; Femal | 2009 |
Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspirin; Aspirin, Dipyridamole Drug Combinatio | 2010 |
Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
Topics: Adult; Aged; Aspirin; Blood Platelets; Blood Specimen Collection; Dipyridamole; Drug Therapy, Combin | 2011 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Dose titration to reduce dipyridamole-related headache.
Topics: Aged; Aspirin; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination; Female; Headac | 2006 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b
Topics: Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Biomarkers; Clopidogrel; Diabetes Mell | 2008 |
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studie | 1981 |
[Role of antiplatelet agents in the prevention of cerebral ischemic accidents].
Topics: Adult; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials as Topic; C | 1983 |
A randomized clinical trial of pentoxifylline and antiaggregants in recent transient ischemic attacks (TIA). A one year follow-up.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Follow-Up Studies; Humans; Isc | 1981 |
[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial].
Topics: Aspirin; Clinical Trials as Topic; Dihydroergotoxine; Dipyridamole; Humans; Ischemic Attack, Transie | 1982 |
Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease.
Topics: Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials a | 1980 |
[anti-platelet therapy or anti-coagulants as prevention in transient ischemic attacks and reversible ischemic stroke].
Topics: Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug The | 1980 |
["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; | 1981 |
Antiplatelet treatment in elderly people with transient ischaemic attacks or ischaemic strokes.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind | 1995 |
Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event.
Topics: Aged; Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemi | 1993 |
European Stroke Prevention Study (ESPS): antithrombotic therapy is also effective in the elderly.
Topics: Actuarial Analysis; Aged; Aspirin; Cause of Death; Cerebral Infarction; Cerebrovascular Disorders; D | 1993 |
European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Demography; Dipyridamole; Double-Blind Method; Fema | 1996 |
Up to date review of the secondary preventive measures for recurrent ischaemic stroke and transient ischaemic episodes.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Hu | 1998 |
Risk factors and antiplatelet therapy in TIA and stroke patients.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Eu | 1998 |
Efficacy of antiplatelet treatment in hypertensive patients with TIA or stroke.
Topics: Aspirin; Blood Pressure; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therapy, | 1998 |
Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Delayed-Action Preparations; Dipyridamole; Disease-Free Su | 1998 |
Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; | 1999 |
[Prevention of vascular complications after cerebral ischemia of arterial origin. European Stroke and Australian Stroke Prevention in Reversible Ischemia Trial (ESPRIT): moderated coagulation, aspirin-dipyridamole combination or aspirin alone?].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Humans; | 1999 |
Cardiac safety in the European Stroke Prevention Study 2 (ESPS2).
Topics: Angina Pectoris; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Longitudinal Studies; My | 2001 |
[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?].
Topics: Administration, Oral; Angina Pectoris; Aspirin; Cause of Death; Cerebral Infarction; Delayed-Action | 2001 |
Guidelines for the management of transient ischemic attacks.
Topics: Anticoagulants; Aspirin; Blood Platelets; Carotid Arteries; Clinical Trials as Topic; Dipyridamole; | 1978 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
An investigation of the effect on platelet function of acetylsalicylic acid, dipyridamole and the two drugs in combination in patients with transient attacks of ischaemia.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Hum | 1979 |
Does aspirin prevent stroke?
Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyr | 1979 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts).
Topics: Animals; Antidepressive Agents, Tricyclic; Aspirin; Blindness; Blood Platelets; Cerebrovascular Diso | 1975 |
Antiplatelet therapy is effective in the prevention of stroke or death in women: subgroup analysis of the European Stroke Prevention Study (ESPS).
Topics: Aspirin; Cause of Death; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; | 1991 |
The European Stroke Prevention Study: results according to sex.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male; | 1991 |
The European Stroke Prevention Study (ESPS): results by arterial distribution.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therap | 1991 |
[Study Group: "Evaluation of the efficacy of therapeutic treatments in cerebrovascular diseases"].
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Female; | 1990 |
European Stroke Prevention Study. ESPS Group.
Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T | 1990 |
Comparative study of pentoxifylline vs antiaggregants in patients with transient ischaemic attacks.
Topics: Aged; Aspirin; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pentoxif | 1989 |
Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized control trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Human | 1988 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
[Randomized clinical study of the efficacy of buflomedil in the prevention of recurrence of cerebral ischemia in comparison with anti-platelet aggregation agents].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Ischemic Attack, Transient; Pyrrolidines; R | 1986 |
Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants.
Topics: Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Female; Humans; Ischemic A | 1985 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage.
Topics: Blood Platelets; Clinical Trials as Topic; Dipyridamole; Humans; Intracranial Aneurysm; Ischemic Att | 1985 |
Controlled trial of dipyridamole in cerebral vascular disease.
Topics: Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Female; Headache; Humans; Ischemi | 1969 |
94 other studies available for dipyridamole and Ischemic Attack, Transient
| Article | Year |
|---|---|
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta | 2022 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
Oral Dipyridamole-Associated Circulatory Collapse.
Topics: Administration, Oral; Aged; Delayed-Action Preparations; Dipyridamole; Humans; Ischemic Attack, Tran | 2018 |
Implications of aspirin biochemistry in the pathobiology of ischemic cerebrovascular disease.
Topics: Aspirin; Dipyridamole; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; Random | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Enzyme-Linked Immunosorbent Assay; Female; Humans; | 2014 |
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi | 2006 |
Is the finding of the PROFESS study consistent with predictions of network meta-analysis?
Topics: Aspirin; Bayes Theorem; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2008 |
The use of aspirin and dipyridamole in the treatment of acute ischaemic stroke/transient ischaemic attack: an audit-based discussion.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Medical Audit; | 2009 |
[Guidelines recommend aspirin/dipyridamole retard in high recurrence risk. Well protected from the second stroke].
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topic | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
TIAs - management in general practice.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Dipyridamole; Dopamine | 2010 |
Antiplatelet therapy for transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders; | 2012 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br | 2013 |
“ Cerebrovascular stressing”: dipyridamole-induced S100B elevation predicts ischemic cerebrovascular events.
Topics: Biomarkers; Coronary Artery Disease; Dipyridamole; Female; Follow-Up Studies; Humans; Ischemic Attac | 2013 |
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Longitu | 2013 |
[Secondary prevention after stroke. 2 platelet inhibitors are better than one].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topic; Dipy | 2002 |
Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug | 2002 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida | 2003 |
[Secondary prevention of ischemic insult and transient cerebral ischemia. Is ASS alone enough?].
Topics: Aspirin; Controlled Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ische | 2003 |
[Secondary prevention after stroke. Doubled performs better].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Controlled Clinical Trials as Topic; Dipyridamole; | 2003 |
[After stroke or TIA. Double protection by second platelet inhibitor].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparatio | 2003 |
[For which patient ASS, clopidogrel or dipyridamole? (interview by Dr. Med. Dirk Einecke)].
Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2004 |
[Summary of the practice guideline 'TIA' (first revision) from the Dutch College of General Practitioners].
Topics: Aspirin; Dipyridamole; Family Practice; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transi | 2005 |
[Summary of the practice guideline 'TIA' (first revision) from the Dutch College of General Practitioners].
Topics: Aspirin; Dipyridamole; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Ischemic Attack, Transi | 2005 |
Use of dipyridamole in patients with recent stroke or TIA.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, | 2005 |
Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Ther | 2005 |
Platelet emboli and ischemia in rabbit's brain caused by ADP or arachidonic acid and the protective effect of ASA and dipyridamole.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Aspirin; Dipyridamole; Intracranial Embolism; Isch | 1977 |
[New DGN-/DSG guidelines].
Topics: Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topi | 2005 |
[The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Ische | 2006 |
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug | 2006 |
[The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Headache; Humans; Ischemic Attack, Transient; Platelet A | 2006 |
[The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Evidence-Based Medicine; Financial Support; Humans; Isch | 2006 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Musical hallucinations induced by drugs.
Topics: Aged, 80 and over; Diagnosis, Differential; Dipyridamole; Female; Hallucinations; Humans; Ischemic A | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Antiplatelet agents for stroke prevention following transient ischemic attack.
Topics: Angioplasty, Balloon; Aspirin; Carotid Artery Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2008 |
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Prescrip | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
Treatment of cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Carotid Arteries; Dicumarol; Dipyridamole; Endarterectomy; Heart Murmurs; H | 1981 |
Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia.
Topics: Adult; Age Factors; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Platelets; Cerebrovas | 1983 |
Plasma thromboglobulin and platelet aggregation index in transient ischaemic attack: effect of aspirin and dipyridamole therapy.
Topics: Adult; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Dipyridamole; Humans; Ischemic Attack, T | 1983 |
Inhibition by dipyridamole of cerebral vasospasm induced in vitro by whole blood.
Topics: Animals; Blood; Cyclic AMP; Dipyridamole; Epoprostenol; Female; In Vitro Techniques; Ischemic Attack | 1983 |
Surgical management of the occluded carotid artery.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr | 1984 |
Atherosclerosis and cerebral ischemic attacks: intakes of cerebrography with xenon133 inhaled and platelet tests in the diagnosis, clinical and therapeutic monitoring; the preventive role of dipyridamole.
Topics: Adult; Aerosols; Aged; Arteriosclerosis; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M | 1984 |
The lame brain at the crossroads: which therapeutic road?
Topics: Aged; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; Dipyridamole | 1984 |
Transient ischemic attacks. Strategies for minimizing stroke risk.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Ischemic Attack, Transient; Middle A | 1984 |
Management of transient cerebral ischaemic attacks by hospital doctors in Scotland.
Topics: Anticoagulants; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Dipyridamole; Female; Humans; | 1983 |
Platelet aggregation in focal cerebral ischemia -a clinical study.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male | 1982 |
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M | 1982 |
Blood platelets and neurological dysfunction.
Topics: Aspirin; Blood Platelets; Child; Dipyridamole; Humans; Ischemic Attack, Transient; Migraine Disorder | 1982 |
[Preventive drug therapy of transient cerebral ischemic attacks].
Topics: Anticoagulants; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Platelet Aggregation; Sul | 1982 |
Circulating platelet aggregates: a chronic platelet activation in patients with transient ischaemic attacks.
Topics: Aspirin; Cerebral Angiography; Dipyridamole; Humans; Intracranial Arteriosclerosis; Ischemic Attack, | 1980 |
For your stroke-prone patients: a guide to drug treatment.
Topics: Aged; Antihypertensive Agents; Aspirin; Brain Diseases; Cerebral Angiography; Cerebrovascular Disord | 1980 |
Antiplatelet drugs after myocardial infarction.
Topics: Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregati | 1980 |
Safety of dipyridamole testing in patients with cerebrovascular disease.
Topics: Aged; Cerebrovascular Disorders; Dipyridamole; Female; Hemodynamics; Humans; Ischemic Attack, Transi | 1995 |
Secondary prevention of stroke--new trials.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Dr | 1998 |
Supplement to the AHA guidelines for the management of transient ischemic attacks.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, | 2000 |
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi | 2000 |
Alert to physicians: possible interaction of aggrenox and adenosine.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparati | 2000 |
Transient ischemic attacks after dipyridamole-aspirin therapy.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug The | 2000 |
[Dipyridamole test in the early detection of cerebrovascular disorders?].
Topics: Cerebrovascular Circulation; Diagnosis, Differential; Dipyridamole; Female; Humans; Ischemic Attack, | 2000 |
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2001 |
[Antiaggregant therapy in cerebrovascular insufficiency in the aged].
Topics: Aged; Aspirin; Blood Platelet Disorders; Dipyridamole; Drug Evaluation; Female; Humans; Ischemic Att | 1979 |
Platelet activation in acute cerebral ischaemia. Serial measurements of platelet function in cerebrovascular disease.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Blood Cell Count; Blood Platelets; Cerebrovascu | 1977 |
Aspirin dose in prevention of transient ischaemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Tra | 1979 |
Treating thromboembolic disease.
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Fibrinolytic Agents; Heart Valve Pros | 1977 |
[Therapy with anticoagulants and platelet aggregation inhibitors in extracranial vascular stenoses and occlusions].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Cerebrovascular Disorders | 1979 |
Transient ischemic attacks due to increased platelet aggregation and adhesiveness. Ultrastructural and functional correlation.
Topics: Adolescent; Adult; Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Blood Platelets; Dipy | 1979 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |
[Transient cerebral ischemic attacks. Treatment program and comparison between anticoagulants and thrombocyte aggregation repressors].
Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male; Time | 1979 |
TIA, stroke, and mitral valve prolapse.
Topics: Adult; Aged; Aspirin; Carotid Artery Thrombosis; Cerebrovascular Disorders; Dipyridamole; Echocardio | 1979 |
Transient ischaemic attacks and increased platelet aggregability associated with oral contraceptives. Treatment with dipyridamole and aspirin.
Topics: Adult; Aspirin; Contraceptives, Oral; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Plat | 1977 |
Dipyridamole for vertebrobasilar insufficiency.
Topics: Basilar Artery; Dipyridamole; Humans; Ischemic Attack, Transient; Male; Middle Aged; Vertebral Arter | 1977 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Apyrase; Arterial Occlusive Diseases; Aspirin; Coronary Dis | 1976 |
Letter: Medical management of transient ischaemic attacks.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; | 1975 |
The pyrimido-pyrimidine derivative RA-642 protects from brain injury in a combined model of permanent focal ischemia and global ischemia reperfusion.
Topics: Animals; Brain; Dipyridamole; Disease Models, Animal; Ischemic Attack, Transient; Lipid Peroxidation | 1992 |
[Carotid endarterectomy for prevention of stroke: comparison of surgical and conservative therapy].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral | 1991 |
Influence of antiplatelet drugs on beta tg and PF4 levels in patients with transient ischemic attacks.
Topics: Adult; Aspirin; Beta-Globulins; beta-Thromboglobulin; Dipyridamole; Female; Humans; Ischemic Attack, | 1985 |
The role of antiplatelet drugs in carotid reconstructive surgery.
Topics: Adult; Aged; Aspirin; Carotid Artery Thrombosis; Carotid Artery, Internal; Dextrans; Dipyridamole; D | 1985 |
Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dicumarol; Dipyridamole; Drug Therapy, Combination; Female; | 1985 |
Sneddon's syndrome: an antiphospholipid antibody syndrome?
Topics: Antibodies; Aspirin; Blood Coagulation Factors; Cardiolipins; Cerebral Infarction; Dipyridamole; Fem | 1988 |
[Prevention of the recurrence of episodes of cerebral ischemia. Therapeutic protocol].
Topics: Aged; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Isoindoles; Male; Middle Aged; Pheny | 1988 |
Prevention of postoperative neurologic deficits after carotid endarterectomy. Is platelet inhibition beneficial?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Dipyrid | 1987 |
Pharmacologic approach to ischemic stroke management.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Dipyridamole; Drug Interactions; Heparin; Human | 1986 |
Spontaneous dissection of the carotid artery: an unusual cause of stroke in younger patients.
Topics: Adult; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Angiography; Cerebrovasc | 1987 |
Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; F | 1985 |
Effect of anticoagulants, vasodilators, and dipyridamole on postischemic cerebral vascular obstruction.
Topics: Amino Alcohols; Animals; Anticoagulants; Bicarbonates; Cerebrovascular Disorders; Dipyridamole; Ethy | 1972 |
[Platelet function disorders and ischemic cerebral accidents. Therapeutic prospects].
Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Cerebrovascular Disorders; Dipyri | 1972 |
[Neuropsychiatry in 1973].
Topics: Aspirin; Bipolar Disorder; Dipyridamole; Heart Diseases; Humans; Hydrocephalus; Hypoxia, Brain; Isch | 1973 |
Address of the president-elect: the indication for various methods of treatment of occlusive cerebrovascular disease.
Topics: Anticoagulants; Aspirin; Blood Pressure; Cardiac Output; Carotid Arteries; Cerebral Angiography; Cer | 1973 |